Healthcare Law Blog

JANUARY 31, 2023

A continued expansion of the psychedelic market in healthcare is expected in 2023 and the market worth of companies operating in this space is anticipated to be over $8 billion by 2028. [vi] Part 2, which governs the medical records of federally assisted substance use treatment programs. In December 2022, the U.S.

COVID-19 105

COVID-19 Medicare Medicare Medicaid 105

HIT Consultant

AUGUST 15, 2022

Approximately 42% of Medicare beneficiaries are enrolled in Medicare Advantage plans—a segment projected to reach 46% by 2025. Due to rapid growth of the 65-and-older portion of the population, Medicare expenditures are forecast to reach $1,559.4 billion in 2028, with spending per enrollee reaching $20,751.

Medicare 52

Medicare Medicare Medicaid Medicaid 52

Healthcare Law Blog

JANUARY 5, 2023

Just in time for the holidays, the Centers for Medicare and Medicaid Services (“CMS”) issued the Contract Year 2024 Proposed Rule for Medicare Advantage organizations (“MAOs”) and Part D sponsors (the “Proposed Rule”). Health Equity in Medicare Advantage. Part D Medication Therapy Management Program.

Medicare 52

Medicare Medicare Medicaid Medicaid 52

Kaiser Health News

AUGUST 12, 2022

First, it would give the federal government the ability to negotiate prices of some drugs purchased by Medicare beneficiaries, a tool that has long been opposed by the drug industry. The drug pricing provision, estimated to save the government nearly $100 billion over 10 years, would require the U.S. “It’s historic.

Medicare 88

Medicare Medicare Prescription Drug Pricing Governance 88